NCT06648655 - A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

November 14, 2024

Primary Completion Date

November 15, 2025

Study Completion Date

November 15, 2025

Conditions

Alcohol Use Disorder (AUD)

Interventions

DRUG

TMP-301

Daily (QD) x 14 weeks.

DRUG

Placebo

Daily (QD) x 14 weeks.

Trial Locations (14)

11516

Neurobehavioral Research, Inc., Cedarhurst

22903

University of Virginia: Center for Leading Edge Addiction Research, Charlottesville

29425

Medical University of South Carolina, Institute of Psychiatry, Charleston

30030

CenExcel iResearch, Decatur

31405

CenExcel iResearch, Savannah

32256

CNS Healthcare- Jacksonville South, Jacksonville

32801

CNS Healthcare, Orlando

33024

Research Centers of America, LLC, Hollywood

33311

Segal Trials - West Broward Outpatient Site, Lauderhill

70448

DelRicht Research - Murphy Clinic, Mandeville

77030

Baylor College of Medicine, Houston

85260

Headlands Research, Scottsdale

87109

IMA Clinical Research, Albuquerque

06511

Yale School of Medicine, New Haven

All Listed Sponsors

lead

Tempero Bio, Inc.

INDUSTRY